NCT03939416

Brief Summary

This clinical research aims to study the effects of the introduction of POLD manual therapy within the protocol of fibromyalgia

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jul 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 2, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 6, 2019

Completed
5.2 years until next milestone

Study Start

First participant enrolled

July 1, 2024

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2024

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 30, 2025

Completed
Last Updated

June 29, 2025

Status Verified

June 1, 2025

Enrollment Period

6 months

First QC Date

May 2, 2019

Last Update Submit

June 26, 2025

Conditions

Keywords

FibromyalgiaChronic pain

Outcome Measures

Primary Outcomes (4)

  • Demographic data

    The following data will be recorded: age, sex, race, children, study start date and final date.

    Participants will be followed for the duration of treatment application, an expected average of 8 weeks.

  • Level of Pain: VAS

    We will use the Visual Analog Pain Scale (VAS), consisting of a line of 10 cm, whose left end coincides with the value 0 (absence of pain) and the right end with the value 10 (maximum pain imaginable), without reference marks intemediate The patient will mark a point in the line corresponding to his pain at the time of the test, the measurement of the centimeters from the left edge will indicate the analogical score of his pain between 0 and 10.

    Participants will be followed for the duration of treatment application, an expected average of 8 weeks.

  • Quality of pain: The Mc Gill pain questionnaire

    The Mc Gill pain questionnaire comprises 62 descriptors distributed in 15 classes and, in turn, in 3 dimensions (sensory, affective and evaluative). A value of pain is obtained for each dimension: sensory pain intensity (VID (S), affective pain intensity (VID (A)) and evaluative pain intensity (VID (E)) The sensory component is evaluated in 7 subclasses. The patient mark one or no descriptor of each subclass, if he scores 1 he scores 1 and if he does not mark none he scores 0. The score of the VID (S) is obtained adding and will be, therefore, between 0 and 7. The affective dimension includes subclasses 8 to 13 and its score ranges from 0 to 6. The evaluative dimension corresponds to subclass 14 and the score of it will be 0 or 1. From the sum of the three, the total score (VID (T)) is obtained, from 0 to 14. In addition, the current pain intensity (VIA) is scored from subclass 15, the score is 0-no pain, 1-mild, 2-annoying, 3-intense, 4-strong, 5-unbearable.

    Participants will be followed for the duration of treatment application, an expected average of 8 weeks.

  • Pain interference: We use the Brief Pain Inventory

    We use the Brief Pain Inventory that gives two main scores: a pain severity score and a pain interference score. The pain severity score is calculated from the four items about pain intensity. Each item is rated from 0, no pain, to 10, pain as bad as you can imagine, and contributes with the same weight to the final score, ranging from 0 to 40. The pain interference score corresponds to the item on pain interference. The seven sub items are rated from 0, does not interfere, to 10, completely interferes, and contributes with the same weight to the final score, ranging from 0 to 70. The first item, pain drawing diagrams (painful and most painful areas) do not contribute to the scoring

    Participants will be followed for the duration of treatment application, an expected average of 8 weeks.

Study Arms (2)

POLD concept treatment

EXPERIMENTAL

Patients treated with rhythmic mobilizations according to the POLD concept, in addition to the standart treatment

Other: Experimental

CONTROL

ACTIVE COMPARATOR

Patients treated with the standart treatment

Other: Control

Interventions

STANDART 1. Physical exercise: degreed joint mobilization, self muscle elongation and postural correction. 2. Sophrology: mental control of insomnia and painful perception 3. Cognitive behavioral therapy: analysis of non-assertive relationship patterns or dependence, dysfunctional beliefs, as well as their consequences, psychoeducation of the disease. Strategies for pain management, anxiety, assertiveness and acceptance of the disease POLD 1. Rhythmic transversal muscle mobilization in posterior chain musculature. 2. General vertebral decompression from the sacrum and pelvis 3. Metameric subcutaneous mobilization 4. Rhythmic vertebral mobilization from the spinous processes.

Also known as: POLD concept treatment + standart treatment
POLD concept treatment
ControlOTHER

STANDART 1. Physical exercise: degreed joint mobilization, self muscle elongation and postural correction. 2. Sophrology: mental control of insomnia and painful perception 3. Cognitive behavioral therapy: analysis of non-assertive relationship patterns or dependence, dysfunctional beliefs, as well as their consequences, psychoeducation of the disease. Strategies for pain management, anxiety, assertiveness and acceptance of the disease

Also known as: Standart treatment
CONTROL

Eligibility Criteria

Age25 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients diagnosed with Fibromyalgia
  • Patients over 25 years old and up to 65 years old, regardless of whether they are women or men.
  • Patients who present pain with a minimum value of 5 on the numerical pain scale from 0 to 10, at the time of beginning the study.
  • Presence of these symptoms in a long period (more than 6 months)

You may not qualify if:

  • Patients with a recent traumatic history.
  • Presence of an irradiation component of neurological origin to upper or lower limbs
  • Patients with neurological alterations, both central and peripheral.
  • Patients who are taking opioid-based analgesic medication.
  • Patients with severe spinal malformations.
  • That they are following any other type of treatment, whether manual or physical agents or alternative or complementary therapies.
  • That they have been treated with infiltrations or similar in a period of less than one year before beginning the study.
  • Patients with a serious psychiatric history such as schizophrenia or psychopathies.
  • Patients who have vestibular problems that do not tolerate oscillation.
  • Patients with heart failure
  • Existence of judicial process of disability

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Specialized hospital unit of fibromyalgia and SD of conical fatigue of L'Hospital Universitari de Santa María (GSS)

Lleida, Catalonia, 25198, Spain

Location

MeSH Terms

Conditions

FibromyalgiaChronic Pain

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesRheumatic DiseasesNeuromuscular DiseasesNervous System DiseasesPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Carmen Campoy, PHD

    Universitat se Lleida

    PRINCIPAL INVESTIGATOR
  • Juan Vicente López Díaz, PHD

    Universitat de Lleida

    STUDY DIRECTOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director

Study Record Dates

First Submitted

May 2, 2019

First Posted

May 6, 2019

Study Start

July 1, 2024

Primary Completion

December 30, 2024

Study Completion

March 30, 2025

Last Updated

June 29, 2025

Record last verified: 2025-06

Locations